INmune Bio INMB 深 沪
已收盘 12-19 16:00:00 美东时间
1.83
+0.010
+0.55%
华盛通- 最 高1.86
- 今 开1.83
- 成交量 34.54万股
- 最 低 1.7901
- 昨 收 1.82
- 总市值 4278.50万
- 52周最高 11.64
- 市盈率 静 --
- 换手率 1.48%
- 52周最低 1.38
- 委 比 -85.61%
- 总股本 2337.98万
- 历史最高 30.37
- 量 比 0.97
- 振 幅 3.84%
- 历史最低 1.38
- 每 手 1
- 风险率 2.86%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多INmune Bio Establishes $65 Million At-The-Market Offering
The latest update is out from Inmune Bio ( ($INMB) ). On December 19, 2025, INm...
今天 06:08
INmune Bio Files For Common Stock Offering Of $65M Shares Of Common Stock
Up to $65,000,000 of Shares of Common Stock INMUNE BIO INC.We have entered into a sales agreement with A.G.P./Alliance Global Partners ("A.G.P." or "the Sales Agent"), dated December 19, 2025 (the "Sales
今天 05:05
INmune Bio Terminates $75M At-the-Market Sales Agreement With RBC Capital Markets And BTIG, Effective December 19, 2025; Prior To Termination, The Co Issued And Sold 1,353,469 Shares Of Common Stock Under The Sales Agreement, Raising Net Proceeds Of ~$10.5M
As previously disclosed, on August 9, 2024, INmune Bio Inc. (the "Company") entered into an Amended and Restated At-The-Market Sales Agreement (the "Sales Agreement") with RBC Capital Markets, LLC ("RBC") and BTIG,
12-11 05:53
Inmune Bio Unveils Promising Alzheimer’s Trial Data
Inmune Bio ( ($INMB) ) just unveiled an announcement. On December 1, 2025, INmu...
12-06 05:43
INmune Bio Announces New Neuroimaging Data From Phase 2 MINDFuL Trial Of XPro1595 In Patients With Early Alzheimer's Disease And Elevated Neuroinflammation
INmune Bio, Inc. (NASDAQ:INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial
12-01 21:07
Inmune Bio Announces New Executive Employment Agreements
Inmune Bio ( ($INMB) ) has issued an update. On November 26, 2025, INmune Bio I...
11-29 02:30
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
INmune Bio announces two presentations at the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD) in San Diego, December 1-4, 2025. The first presentation by Kim A. Staats, PhD, will discuss Phase 2 MINDFuL trial results for XPro1595, a selective soluble TNF neutralizer, in early Alzheimer's disease with inflammation. The second, by Sarah Barnum, PhD, will validate the Early Mild Alzheimer’s Cognitive Composite (EMACC) through blood-bas...
11-18 13:00
Inmune Bio outlines 2026 regulatory milestones and cash runway through Q4 2026
Earnings Call Insights: INmune Bio (INMB) Q3 2025 Management View David Moss, President, CEO, Treasurer, Secretary & Director, stated the company has transitioned its focus after concluding the Alzhei...
10-31 11:17
INmune Bio Q3 Adj. EPS $(0.24) Beats $(0.33) Estimate
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.33) by 26.15 percent. This is a 60 percent increase over losses of $(0.60) per share from the same
10-31 04:14
Earnings Scheduled For October 30, 2025
Companies Reporting Before The Bell • Altria Group (NYSE:MO) is projected to re...
10-30 19:12
